Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
Form 144 notice for SOPHIA GENETICS SA (SOPH) discloses a proposed sale of 6,833 common shares through Morgan Stanley Smith Barney with an aggregate market value of $23,847.17. The filing lists the approximate sale date as 08/19/2025 and shows 67,579,560 shares outstanding. The shares were acquired as restricted stock units from the issuer on 08/18/2025 with payment noted on 08/18/2025. The filing also reports recent 10b5-1 sales by PHILIPPE MENU totaling 6,639 shares across several dates in May–July 2025 with listed gross proceeds.
SOPHiA GENETICS SA prospectus supplement discloses share capital, equity incentives and corporate governance provisions relevant to debt and equity offerings. As of June 30, 2025 the company reported options and awards that could dilute equity: 495,980 shares from an Incentive Stock Option Plan (WAEP $3.18), 2,295,990 from a 2019 plan (WAEP $4.97), 11,558,048 from a 2021 Equity Incentive Plan (WAEP $5.79), 3,194,328 RSUs, 3,838,901 additional shares reserved under the 2021 plan, 400,000 warrants (exercise $4.9992) and 11,741,660 treasury shares.
The filing also describes shareholder authority and board powers, authorized conditional share capital and a capital range enabling the board to increase or decrease share capital by up to 50% within a shareholder-determined period not exceeding five years. It lists circumstances permitting issuance without pre-emptive rights, permitted offering methods, and certain exemptions and Exchange Act obligations applicable if the company ceases to qualify as a foreign private issuer.
Schedule 13G filing: On 27 June 2025 Akre Capital Management, LLC (ACM), Braddock Partners Offshore, LP and Braddock Capital Offshore, LLC jointly filed a Schedule 13G reporting a beneficial position in SOPHiA GENETICS SA (CUSIP H82027105).
The reporting persons collectively hold 3,719,140 ordinary shares, representing 5.6 % of the outstanding class. All voting and dispositive authority over the shares is shared; each entity reports zero sole voting or dispositive power and full shared power over the entire stake, triggering the 5 % disclosure threshold under Section 13(d).
ACM is organized in Delaware and operates as an investment adviser, while Braddock Partners Offshore, LP is a Cayman Islands limited partnership and Braddock Capital Offshore, LLC is a Delaware limited-liability company. The certification states that the securities were acquired ‘not for the purpose of or with the effect of changing or influencing the control’ of the issuer. No additional group members, subsidiary acquisitions, or 5 %-or-less disclaimers are indicated. An Exhibit A Joint Filing Agreement accompanies the submission.
Form 144 overview: SOPHiA GENETICS SA (ticker SOPH) has filed a Form 144 indicating the proposed sale of insider-held shares under Rule 144 of the Securities Act of 1933.
- Seller & relationship: The filing lists one unnamed insider ("person for whose account the securities are to be sold"). No further relationship data is provided in the snippet.
- Securities to be sold: 18,443 shares of common stock.
- Estimated market value: USD 56,066.72, implying an indicative share price of roughly USD 3.04.
- Broker: Morgan Stanley Smith Barney LLC, Executive Financial Services, New York.
- Planned trade date & venue: On or about 20 June 2025 on the NASDAQ.
- Shares outstanding: 66,687,085. The proposed sale represents approximately 0.028% of total shares outstanding—not material from a dilution perspective.
- Source of shares: Restricted Stock Units acquired 18 June 2025; not a gift.
- Prior 3-month sales: The filer reports "Nothing to Report," indicating no other recent insider sales by this individual that must be aggregated.
Investor takeaway: The filing signals a routine disposal of a small block of shares by an insider. Given the limited size relative to total float and the absence of any cited adverse information, the market impact is likely negligible. Nevertheless, investors monitoring insider activity may note the transaction when evaluating sentiment and liquidity conditions.